UPDATE: Zenodo migration postponed to Oct 13 from 06:00-08:00 UTC. Read the announcement.

Journal article Open Access

Vigabatrin and newer interventions in succinic semialdehyde dehydrogenase deficiency

Gropman, Andrea


DataCite XML Export

<?xml version='1.0' encoding='utf-8'?>
<resource xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns="http://datacite.org/schema/kernel-4" xsi:schemaLocation="http://datacite.org/schema/kernel-4 http://schema.datacite.org/meta/kernel-4.1/metadata.xsd">
  <identifier identifierType="URL">https://zenodo.org/record/1229117</identifier>
  <creators>
    <creator>
      <creatorName>Gropman, Andrea</creatorName>
      <givenName>Andrea</givenName>
      <familyName>Gropman</familyName>
    </creator>
  </creators>
  <titles>
    <title>Vigabatrin and newer interventions in succinic semialdehyde dehydrogenase deficiency</title>
  </titles>
  <publisher>Zenodo</publisher>
  <publicationYear>2003</publicationYear>
  <dates>
    <date dateType="Issued">2003-01-01</date>
  </dates>
  <resourceType resourceTypeGeneral="JournalArticle"/>
  <alternateIdentifiers>
    <alternateIdentifier alternateIdentifierType="url">https://zenodo.org/record/1229117</alternateIdentifier>
  </alternateIdentifiers>
  <relatedIdentifiers>
    <relatedIdentifier relatedIdentifierType="DOI" relationType="IsIdenticalTo">10.1002/ana.10626</relatedIdentifier>
  </relatedIdentifiers>
  <rightsList>
    <rights rightsURI="https://creativecommons.org/publicdomain/zero/1.0/legalcode">Creative Commons Zero v1.0 Universal</rights>
    <rights rightsURI="info:eu-repo/semantics/openAccess">Open Access</rights>
  </rightsList>
  <descriptions>
    <description descriptionType="Abstract">Succinic semialdehyde dehydrogenase (SSADH) deficiency is a rare disorder characterized by an inborn error of the catabolism of the inhibitory neurotransmitter GABA. Because of the deficiency of SSADH, the final enzyme of the GABA degradation pathway, the substrate, succinic semialdehyde, is shunted towards production of 4‐hydroxybutyric acid (γ‐hydroxybutyric acid). Elevations of γ‐hydroxybutyric acid can be detected in the physiologic fluids of patients with SSADH deficiency, and forms the mainstay of diagnosis. The clinical features of SSADH deficiency include nonspecific neurologic manifestations such as mental retardation/developmental delay, absent speech, hypotonia, nonprogressive ataxia, features of autism or pervasive developmental delay, developmental language delay (dyspraxia, receptive, and expressive delays), and occasionally, seizures. Although the metabolic pathway has been established, it is not known whether insufficient GABA and/or excess γ‐hydroxybutyric acid contribute to the disease phenotype. Pharmacological therapy in patients with this disorder has been limited to vigabatrin, an anticonvulsant that blocks GABA transaminase. This review will discuss therapeutic options in SSADH deficiency, on the basis of patient experience, and preliminary work using a murine model. Finally, a discussion of adjunctive therapies will be included. Ann Neurol 2003;54 (suppl 6):S66–S72</description>
  </descriptions>
</resource>
278
244
views
downloads
Views 278
Downloads 244
Data volume 24.1 MB
Unique views 275
Unique downloads 240

Share

Cite as